Dubinsky, Marla. C.; Deputy Scientific Secretary IOIBD ; Icahn School of Medicine at Mount Sinai, New York, New York, United States
Collins, Rory; UK Biobank, Manchester, United Kingdom ; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
Abreu, Maria T.; Chair, IOIBD ; Division of Gastroenterology and Hepatology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, United States
Jairath, V.
Lewis, J. D.
Lindsay, J.
Merad, M.
Ng, S.
Panaccione, R.
Panes, J.
Sands, B.
Siegal, C. A.
Singh, Suraj Kumar ; Université de Liège - ULiège > Département de physique > Physique expérimentale des matériaux nanostructurés
Vermeire, S.
Ahuja, V.
Allez, M.
Ananthakrishnan, A.
Bemelman, W.
Braun, J.
Colombel, J.-F.
Danese, S.
D'Haens, G.
D'Hoore, A.
Dignass, A.
Dotan, I.
Gassul, M. A.
Griffiths, A.
Halfvarson, J.
Hanauer, S.
Kotze, P.
Koutroubakis, I.
Loftus, E.
Magro, F.
Mantzaris, G.
Mary, J.-Y.
McGovern, D.
Munkholm, P.
O'Morain, C.
Panis, Y.
Peyrin-Biroulet, L.
Prantera, C.
Ran, Z.
Siegmund, B.
Silverberg, M.
Stange, E.
Targan, S.
Tysk, C.
Travis, S.
Vatn, M.
Yamamoto-Furusho, Y.
Aarts, J.
Abhyankar, B.
Ahmad, H.
Aranda, R.
Arora, V.
Benjacoub, J.
Berg, S.
Besuyen, R.
Bojic, D.
Carriero, V.
Cataldi, F.
D'Agay, L.
Delgado-Aros, S.
Giannasca, P.
Goyal, K.
Greinwald, R.
Gropper, S.
Kageyama, S.
Laoun, R.
Levesque, B.
Lissoos, T.
Modesto, I.
Mohrbacher, R.
Mueller, R.
Naegeli, A.
Naik, S.
Nguyen, D.
Niezychowski, W.
O'Brien, C.
Odnoletkova, I.
Oortwijn, A.
Park, K. K. T.
Radziszewski, W.
Salese, L.
Spleiss, J.
Stancati, A.
Tatro, A.
Thompson, J.
Hofmann, R.
Zambrano, J.
Zhou, W.
Zigmont, E.
International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)
Mayo ClinicBoehringer Ingelheim, BIAmgenBristol-Myers Squibb, BMSPfizerRocheGilead SciencesAbbVieUniversity of Miami, UMNorthwestern University, NUIcahn School of Medicine at Mount Sinai, ISMMSPerelman School of Medicine, University of PennsylvaniaTakeda Pharmaceutical Company, TPCJanssen PharmaceuticalsCumming School of Medicine, University of Calgary, CSMCedars-Sinai Medical Center, CSEA Pharma Co., Ltd.British Heart Foundation, BHFUniversity of OxfordKU LeuvenChinese University of Hong Kong, CUHKAll-India Institute of Medical Sciences, AIIMSUniversitaire Ziekenhuizen Leuven, KU Leuven, UZ LeuvenTillotts Pharma
Danese, S., Schabel, E., Ainsworth, M.A., et al. Challenges and opportunities for IBD drug development: from early stage to regulatory approval. Gut 69 (2020), 1157–1161.
Khanna, R., Jairath, V., Vande Casteele, N., et al. Efficient early drug development for ulcerative colitis. Gastroenterology 150 (2016), 1056–1060.
Collins, R., Bowman, L., Landray, M., et al. The magic of randomization versus the myth of real-world evidence. N Engl J Med 382 (2020), 674–678.
Harris, M.S., Wichary, J., Zadnik, M., et al. Competition for clinical trials in inflammatory bowel diseases. Gastroenterology 157 (2019), 1457–1461.e2.
Johnson, C., Barnes, E.L., Zhang, X., et al. Trends and characteristics of clinical trials participation for inflammatory bowel disease in the United States: a report from IBD partners. Crohns Colitis, 360(2), 2020, otaa023.
Sharp, D., Ringer, S., Park, K.T., et al. Listening to the patient: improving the design and conduct of clinical trials in inflammatory bowel diseases. Crohns Colitis, 360(2), 2020, otaa011.
McGonagle, D., McDermott, M.F., A proposed classification of the immunological diseases. PLoS Med, 3, 2006, e297.
Momozawa, Y., Dmitrieva, J., Théâtre, E., et al. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nat Commun, 9, 2018, 2427.
Torres, J., Colombel, J.F., Genetics and phenotypes in inflammatory bowel disease. Lancet 387 (2016), 98–100.
Targan, S.R., Hanauer, S.B., van Deventer, S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997), 1029–1035.
Martin, J.C., Chang, C., Boschetti, G., et al. Single-cell analysis of Crohn's disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy. Cell 178 (2019), 1493–1508.e20.
Ha, C., Ullman, T.A., Siegel, C.A., et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 10 (2012), 1002–1007 quiz e78.
Higgins, P.D.R., Harding, G., Leidy, N.K., et al. Development and validation of the Crohn's disease patient-reported outcomes signs and symptoms (CD-PRO/SS) diary. J Patient Rep Outcomes, 2, 2017, 24.
Dulai, P.S., Jairath, V., Khanna, R., et al. Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 51 (2020), 1047–1066.
Ozaki, R., Kobayashi, T., Okabayashi, S., et al. Histological risk factors to predict clinical relapse in ulcerative colitis with endoscopically normal mucosa. J Crohns Colitis 12 (2018), 1288–1294.
Kairalla, J.A., Coffey, C.S., Thomann, M.A., et al. Adaptive trial designs: a review of barriers and opportunities. Trials, 13, 2012, 145.
US Food and Drug Administration. Adaptive designs for clinical trials of drugs and biologics. Guidance for industry. Available at: https://www.fda.gov/media/78495/download Accessed January 8, 2021.
